Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy.
作者信息
Schambach Axel, Morgan Michael, Fehse Boris
机构信息
Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
出版信息
Mol Ther. 2021 Sep 1;29(9):2631-2633. doi: 10.1016/j.ymthe.2021.08.013. Epub 2021 Aug 24.
Abstract
摘要
相似文献
1
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy.
Mol Ther. 2021 Sep 1;29(9):2631-2633. doi: 10.1016/j.ymthe.2021.08.013. Epub 2021 Aug 24.
2
Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.
Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. eCollection 2022.
3
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Cytotherapy. 2014 Sep;16(9):1257-69. doi: 10.1016/j.jcyt.2014.05.022.
4
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.
Blood. 2021 Oct 21;138(16):1504-1509. doi: 10.1182/blood.2021010813.
5
CAR T-cell therapy in refractory large B-cell lymphoma.
Lancet Oncol. 2018 Jan;19(1):e19. doi: 10.1016/S1470-2045(17)30928-2. Epub 2017 Dec 14.
6
Advances and challenges in CAR-T cell-mediated immunotherapy.
Int Rev Immunol. 2022;41(6):565-566. doi: 10.1080/08830185.2022.2111107.
7
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23.
8
[Exploration of CAR-T cell combination therapy strategies in lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):873-876. doi: 10.3760/cma.j.issn.0253-2727.2022.10.014.
9
The Promise and Challenges of CAR-T Gene Therapy.
JAMA. 2017 Dec 12;318(22):2167-2169. doi: 10.1001/jama.2017.15605.
10
A review of chimeric antigen receptor T-cells in lymphoma.
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
引用本文的文献
1
Generation and GMP scale-up of human CAR-T cells using non-viral transposons for B cell malignances.
Mol Ther Methods Clin Dev. 2025 Jan 31;33(1):101425. doi: 10.1016/j.omtm.2025.101425. eCollection 2025 Mar 13.
2
Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner.
Mol Ther. 2025 Jan 3. doi: 10.1016/j.ymthe.2024.12.057.
3
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.
Front Cell Dev Biol. 2024 Nov 18;12:1491282. doi: 10.3389/fcell.2024.1491282. eCollection 2024.
4
CAR-T cell manufacturing: Major process parameters and next-generation strategies.
J Exp Med. 2024 Feb 5;221(2). doi: 10.1084/jem.20230903. Epub 2024 Jan 16.
5
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors.
Sci Adv. 2023 Dec;9(48):eadg9721. doi: 10.1126/sciadv.adg9721. Epub 2023 Dec 1.
6
Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128.
7
Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy.
Mol Ther Methods Clin Dev. 2023 Mar 14;29:145-159. doi: 10.1016/j.omtm.2023.03.003. eCollection 2023 Jun 8.
8
Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.
Hematol Oncol Clin North Am. 2022 Aug;36(4):745-768. doi: 10.1016/j.hoc.2022.03.007. Epub 2022 Jun 27.
9
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Mol Ther. 2022 Oct 5;30(10):3155-3175. doi: 10.1016/j.ymthe.2022.06.006. Epub 2022 Jun 16.
10
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.
Mol Ther. 2022 Jul 6;30(7):2401-2415. doi: 10.1016/j.ymthe.2022.05.018. Epub 2022 May 20.
本文引用的文献
1
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.
Blood. 2021 Oct 21;138(16):1504-1509. doi: 10.1182/blood.2021010813.
2
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.
Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858.
3
Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.
Blood Adv. 2019 Aug 13;3(15):2317-2322. doi: 10.1182/bloodadvances.2019000219.
4
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.
5
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells.
Nat Commun. 2017 Sep 8;8(1):498. doi: 10.1038/s41467-017-00609-1.
6
Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells.
Mol Ther. 2016 Mar;24(3):592-606. doi: 10.1038/mt.2016.11. Epub 2016 Jan 12.
7
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.
Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.
8
T-cell receptor diversity prevents T-cell lymphoma development.
Leukemia. 2012 Dec;26(12):2499-507. doi: 10.1038/leu.2012.142. Epub 2012 May 30.
9
Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery.
Nucleic Acids Res. 2011 Sep 1;39(16):7147-60. doi: 10.1093/nar/gkr384. Epub 2011 May 23.
Zotero 插件